Jade Biosciences Inc
JBIO
Company Profile
Business description
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Contact
221 Crescent Street
Building 23, Suite 105
WalthamMA02453
USAT: +1 781 312-3013
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,439.10 | 73.40 | 0.88% |
| CAC 40 | 7,593.87 | 38.00 | 0.50% |
| DAX 40 | 22,496.98 | 71.15 | 0.32% |
| Dow JONES (US) | 40,752.96 | 83.60 | 0.21% |
| FTSE 100 | 8,496.80 | 1.95 | 0.02% |
| HKSE | 22,493.17 | 373.76 | 1.69% |
| NASDAQ | 17,710.74 | 264.40 | 1.52% |
| Nikkei 225 | 36,717.49 | 265.19 | 0.73% |
| NZX 50 Index | 12,311.33 | 162.73 | 1.34% |
| S&P 500 | 5,604.14 | 35.08 | 0.63% |
| S&P/ASX 200 | 8,218.50 | 72.90 | 0.89% |
| SSE Composite Index | 3,279.03 | 7.62 | -0.23% |